

## SPECIALTY GUIDELINE MANAGEMENT

### TAFINLAR (dabrafenib)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

###### A. FDA-Approved Indications

1. Tafinlar is indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test.
2. Tafinlar is indicated, in combination with trametinib, for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
3. Tafinlar is indicated, in combination with trametinib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.

Limitation of Use: Tafinlar is not indicated for treatment of patients with wild-type BRAF melanoma or wild-type BRAF NSCLC.

###### B. Compendial Uses

Melanoma (including brain metastases), BRAF V600 activating mutation-positive

All other indications are considered experimental/investigational and are not a covered benefit.

##### II. CRITERIA FOR INITIAL APPROVAL

###### A. **Melanoma**

Authorization of 12 months may be granted for treatment of melanoma (including brain metastases from melanoma) with a BRAF V600 activating mutation (e.g., BRAF V600E or BRAF V600K mutation).

###### B. **Non-Small Cell Lung Cancer (NSCLC)**

Authorization of 12 months may be granted for treatment of BRAF V600E mutation-positive NSCLC.

##### III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

##### IV. REFERENCES

1. Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corporation; June 2017.
2. The NCCN Drugs & Biologics Compendium® ©2017 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed March 19, 2017.
3. The NCCN Clinical Practice Guidelines in Oncology™ Melanoma (Version 1.2017). ©2016 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed March 17, 2017.
4. The NCCN Clinical Practice Guidelines in Oncology™ Central Nervous System Cancers (Version 1.2016). ©2016 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed March 17, 2017.
5. The NCCN Clinical Practice Guidelines in Oncology™ Non-Small Cell Lung Cancer (Version 4.2017). ©2017 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed March 17, 2017.

Tafinlar SGM P2017a

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. are both independent licensees of the Blue Cross and Blue Shield Association. The Blue Cross and Blue Shield Names and Symbols are registered trademarks of the Blue Cross and Blue Shield Association. ® Registered trademark of CareFirst of Maryland, Inc.